肿瘤细胞治疗研究
英文原题:Patient-derived bladder cancer organoid model to predict sensitivity and feasibility of tailored precision therapy.
Patient-derived bladder cancer organoid model to predict sensitivity and feasibility of tailored precision therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们的研究凸显了 BCO 在促进膀胱癌个体化医疗发展、提高膀胱癌治疗药物研发效率方面的潜力。
膀胱癌是一种常见且高度异质的恶性肿瘤,预后相对较差。因此,个体化治疗策略对于改善患者结局至关重要。
我们建立了一种高效的膀胱癌类器官(BCO)三维体外培养系统,可保留类器官与原患者肿瘤的相似性及不同个体间的异质性。此外,我们构建了靶向B7H3的嵌合抗原受体(CAR)T细胞,并通过与BCO共培养评估其抗肿瘤功能。
BCO与人类肿瘤特征高度相似,可用于检测个体对铂类药物和奥拉帕利治疗的敏感性。与CAR-T 细胞共培养显示了特异性抗原识别和免疫活化,提示其在免疫治疗中的潜力。
本研究凸显BCO有望促进膀胱癌个体化医疗的发展,并提高膀胱癌治疗药物发现的效率。
Bladder cancer is a common and highly heterogeneous malignant tumor with a relatively poor prognosis. Thus, personalized treatment strategies for bladder cancer are essential for improving patient outcomes.
We developed an efficient 3-dimensional in vitro organoid culture system for bladder cancer organoids (BCOs), which maintains the homology with the original patient tumors and the heterogeneity between different individuals. In addition, we constructed chimeric antigen receptor (CAR)-T cells targeting B7H3 and evaluated the antitumor function of CAR-T cells by coculturing them with BCOs.
The BCOs closely resembled the characteristics of human tumors and were used to test individual sensitivity to platinum-based drugs and olaparib therapy. Coculture with CAR-T cells demonstrated specific antigen recognition and immune activation, indicating their potential in immunotherapy.
Our study highlights the potential of BCOs to facilitate the development of personalized medicine for bladder cancer and improve the efficiency of drug discovery for bladder cancer therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。